

BIENAIME JEAN JACQUES

Form 4

December 21, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
12/21/2012

NOVATO, CA 94949  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	12/21/2012 <sup>(1)</sup>	12/21/2012	M		3,000 A \$ 12.99	170,691	D
Common Stock	12/21/2012 <sup>(2)</sup>	12/21/2012	M		6,000 A \$ 12.99	176,691	D
Common Stock	12/21/2012 <sup>(1)</sup>	12/21/2012	S		3,000 D \$ 48.5708	173,691	D
Common Stock	12/21/2012 <sup>(2)</sup>	12/21/2012	S		6,000 D \$ 48.5708	167,691	D

(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) Common Stock	\$ 12.99	12/21/2012 <sup>(1)</sup>	12/21/2012	M	3,000	11/11/2006 <sup>(4)</sup> 05/10/2016	Common Stock	3,000
Stock Option (right to buy) Common Stock	\$ 12.99	12/21/2012 <sup>(2)</sup>	12/21/2012	M	6,000	11/11/2006 <sup>(4)</sup> 05/10/2016	Common Stock	6,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	X		Chief Executive Officer	

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

12/21/2012

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 10, 2012.
- (2) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on March 12, 2012.

- The price in Column 4 is a weighted average price. The prices actually received ranged from \$48.35 to \$48.91. The reporting person will
- (3) provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  - (4) Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.